Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

The Use of Bedaquiline in the Treatment of Multi-Drug Resistant Tuberculosis: Interim Policy Guidance

Guideline
The Use of Bedaquiline in the Treatment of Multi-Drug Resistant Tuberculosis: Interim Policy Guidance

This interim guidance provides advice on the inclusion of bedaquiline in the combination therapy of MDR-TB in accordance with the existing WHO Guidelines for the Programmatic Management of Drug-resistant TB (2011 Update).

Author:

World Health Organization, Global TB Programme

Topic:

MDR TB, TB Treatment, Treatment- Medication Information

View Webpage

Related Materials

Multi-Drug Resistant Tuberculosis

This video summarizes the key elements of the multi-faceted, private-public partnership that has been assembled by Lilly to meet the challenge of MDR-TB. Several world-recognized experts from academia, international agencies, and from within the company talk about the challenges that developing nations face in implementing sound containment programs given the lack of awareness, adequately trained personnel and access to affordable drugs.

Webpage

MMWR: Provisional CDC Guidelines for the Use and Safety Monitoring of Bedaquiline Fumarate (Sirturo) for the Treatment of Multidrug-Resistant Tuberculosis

This report provides provisional CDC guidelines for FDA-approved and unapproved, or off-label, uses of bedaquiline in certain populations who were not included in the clinical trials for the drug. These guidelines are intended for health-care professionals who might use bedaquiline for the treatment of MDR TB for indicated and off-label uses. Aspects of these guidelines are not identical to current FDA-approved labeling for bedaquiline. Bedaquiline should be used with clinical expert consultation as part of combination therapy (minimum four-drug treatment regimen) and administered by direct observation to adults aged =18 years with a diagnosis of pulmonary MDR TB (Food and Drug Administration. Use of the drug also can be considered for individual patients in other categories (e.g., persons with extrapulmonary TB, children, pregnant women, or persons with HIV or other comorbid conditions) when treatment options are limited. However, further study is required before routine use of bedaquiline can be recommended in these populations.

Report

Treatment of Drug-Resistant Tuberculosis

This fact sheet discusses treatment of drug-resistant TB. A table outlining potential drug regimens for treating drug-resistant TB is also provided.

Fact Sheet

Global resources for the prevention,
management, and elimination of TB.